Long-Term Sex Hormone Treatment in Transgender Care Tied to Changes in Body Composition
By Lori Solomon HealthDay Reporter
TUESDAY, Dec. 3, 2024 -- Long-term sex hormone treatment in transgender individuals can lead to significant changes in body composition and risk factors for cardiovascular disease, according to a study published online Nov. 27 in the Journal of Internal Medicine.
Tommy R. Lundberg, Ph.D., from the Karolinska Institute in Stockholm, and colleagues examined changes in body composition, muscle volumes, and fat distribution as well as muscle strength, arterial stiffness, and cardiometabolic biomarkers in 17 transgender men (TM) and 16 transgender women (TW) at baseline and after one and five to six years of hormone therapy.
The researchers found that skeletal muscle size increased in TM (21 percent after six years) and decreased in TW (7 percent after five years). Muscle strength was unchanged in TW but increased 18 percent after six years in TM. There was almost complete muscle fat infiltration toward the affirmed sex phenotype after one year of therapy in both TM and TW. For fat volume distribution, TW showed increased total adiposity but decreased visceral fat volume, while TM showed increased visceral fat (70 percent) and liver fat, but relatively stable total adipose tissue levels. There were no changes in arterial stiffness and blood pressure, but there was a significant increase in triglyceride and low-density lipoprotein cholesterol levels and a decrease in high-density lipoprotein levels in TM after six years.
"These unique longitudinal data underscore the importance of continued clinical monitoring of the long-term health effects of gender-affirming hormone therapy in both TW and, perhaps especially, TM," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Increased Risk for CVD Seen for Women With Premenstrual Disorders
THURSDAY, July 17, 2025 -- Women with premenstrual disorders (PMDs) have an increased risk for cardiovascular diseases (CVDs), according to a study published online July 11 in...
Consistent Physical Activity Linked to Reduced All-Cause, CVD Mortality
FRIDAY, July 11, 2025 -- Consistently and increasingly accumulated physical activity (PA) is associated with a reduced risk for all-cause and cardiovascular disease (CVD)...
Almost 15 Percent of U.S. Seniors Use Aspirin for Primary Prevention
THURSDAY, July 10, 2025 -- Almost 15 percent of U.S. adults aged 50 to 80 years are taking aspirin for primary cardiovascular disease prevention, according to a brief report...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.